A MolEcularly Guided Anti-Cancer Drug Off-Label Trial
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a prospective, open-label, non-randomized combined basket- and umbrella trial divided
in two parts; a limited feasibility-oriented part 1 including 154 patients and 3 treatment
cohorts and part 2 that will include an expanded cohort of patients and treatment cohorts.
The overall aims of the study are to test the feasibility, safety and efficacy of
comprehensive genomic profiling on fresh tumor biopsies as a basis for treatment decision
making and to compare two different sequencing, bioinformatics and decision-making platforms
(part 1). Also to evaluate the efficacy and safety of off-label treatment with cancer drugs
in patients selected based on genomic biomarker matching.